Last reviewed · How we verify
EN41-UGR7C HIV vaccine
EN41-UGR7C HIV vaccine is a Biologic drug developed by PX'Therapeutics. It is currently in Phase 1 development. Also known as: EN41-UGR7C adjuvanted with Alum.
At a glance
| Generic name | EN41-UGR7C HIV vaccine |
|---|---|
| Also known as | EN41-UGR7C adjuvanted with Alum |
| Sponsor | PX'Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EN41-UGR7C HIV vaccine CI brief — competitive landscape report
- EN41-UGR7C HIV vaccine updates RSS · CI watch RSS
- PX'Therapeutics portfolio CI
Frequently asked questions about EN41-UGR7C HIV vaccine
What is EN41-UGR7C HIV vaccine?
EN41-UGR7C HIV vaccine is a Biologic drug developed by PX'Therapeutics.
Who makes EN41-UGR7C HIV vaccine?
EN41-UGR7C HIV vaccine is developed by PX'Therapeutics (see full PX'Therapeutics pipeline at /company/px-therapeutics).
Is EN41-UGR7C HIV vaccine also known as anything else?
EN41-UGR7C HIV vaccine is also known as EN41-UGR7C adjuvanted with Alum.
What development phase is EN41-UGR7C HIV vaccine in?
EN41-UGR7C HIV vaccine is in Phase 1.
Related
- Manufacturer: PX'Therapeutics — full pipeline
- Also known as: EN41-UGR7C adjuvanted with Alum
- Compare: EN41-UGR7C HIV vaccine vs similar drugs
- Pricing: EN41-UGR7C HIV vaccine cost, discount & access